Key Highlights

  • Vivani Medical (NASDAQ:VANI) was up 10.61 percent to USD 1.21; SLIM-1 top-line data are guided for November 2026.
  • BioRestorative Therapies (NASDAQ:BRTX) was up 8.55 percent to USD 1.52; Phase 2 topline data are expected in the second quarter of 2027.
  • ProMIS Neurosciences (NASDAQ:PMN) was up 12.39 percent to USD 3.84; 12-month PMN310 data are expected in the first quarter of 2027.
  • Tiziana Life Sciences (NASDAQ:TLSA) was up 12.50 percent to USD 0.9000; the company reported trend data in 14 patients on May 19, 2026.
  • Unicycive Therapeutics (NASDAQ:UNCY) was down 9.09 percent to USD 3.40; the FDA set a PDUFA date of March 25, 2027.

Vivani Medical (NASDAQ:VANI): A Readout Guided for This Month

Vivani Medical (NASDAQ:VANI) was up 10.61 percent to USD 1.21 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified as the catalyst, and the shares are a Penny Stock with the usual Volatility and dilution risks.

The company said top-line data from the Phase 1 SLIM-1 trial of NPM-139, a semaglutide implant, are expected in November 2026. The study dosed 20 participants, ten on NPM-139 and ten on Wegovy for four weeks, so it is small. Cash was USD 20.8 million at June 30, 2026, and no cash runway was stated in the release reviewed.

BioRestorative Therapies (NASDAQ:BRTX): A 2027 Spine Readout

BioRestorative Therapies (NASDAQ:BRTX) was up 8.55 percent to USD 1.52 in pre-market trading on November 2, 2026. The implied prior close was about USD 1.40 (calculated). No company announcement from late October to November 2, 2026 was identified, so the gain may reflect momentum and thin liquidity.

In a May 26, 2026 press release, the company said topline Phase 2 safety and efficacy data for BRTX-100 are expected in the second quarter of 2027. The randomized, sham-controlled study enrolled about 99 patients with chronic lumbar disc disease, and BRTX-100 holds Fast Track designation. That release gave no cash balance, so a company filing should be consulted for liquidity.

ProMIS Neurosciences (NASDAQ:PMN): Alzheimer's Data in Early 2027

ProMIS Neurosciences (NASDAQ:PMN) was up 12.39 percent in pre-market trading on November 2, 2026, to USD 3.84. No announcement from late October to November 2, 2026 was identified, so the gain may be a rebound.

The company expects 12-month topline data from the PRECISE-AD Phase 1b study of PMN310 in the first quarter of 2027. Dr. Ivana Rubino became Chief Commercial Officer effective October 5, 2026. A January 30, 2026 private Placement offered up to about USD 175 million, with about USD 75 million upfront, and Warrant exercises could add shares.

Tiziana Life Sciences (NASDAQ:TLSA): Trend Data, Not Proof

Tiziana Life Sciences (NASDAQ:TLSA) was up 12.50 percent to USD 0.9000 in pre-market trading on November 2, 2026, which is below USD 1. No announcement dated late October to November 2, 2026 was identified as the trigger.

On May 19, 2026 the company reported expanded access data for intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis. Fatigue scores improved by at least 4 points in 9 of 14 patients, or 64 percent, but the company noted the results were not statistically significant and were a Trend Analysis only. A randomized Phase 2a study is underway, and the company has announced registered direct offerings, including an oversubscribed USD 8.8 million one.

Unicycive Therapeutics (NASDAQ:UNCY): A Dated Regulatory Decision

Unicycive Therapeutics (NASDAQ:UNCY) was down 9.09 percent at USD 3.40 in pre-market trading on November 2, 2026. No company announcement dated November 2, 2026 was identified. Securities class action notices circulated on October 29 and 30, 2026 may be weighing on sentiment, and they are allegations rather than findings.

According to an October 21, 2026 company press release, the FDA accepted the resubmitted application for oxylanthanum carbonate and set a PDUFA goal date of March 25, 2027. A PDUFA date is a review target and does not guarantee approval. The company last reported results on August 12, 2026, and a clinical-stage firm without product Revenue may need further capital.

Where Things Stand

The five names share dated or guided milestones, from the SLIM-1 readout in November 2026 to the March 25, 2027 PDUFA date and the first and second quarter 2027 readouts. Most of the pre-market moves had no identified company announcement, so they may reflect positioning or rebounds. Readers may watch for filings that explain the moves, financing updates and the timing of each data release, remembering that trial outcomes are binary.